When should acute exacerbations of copd be treated with systemic corticosteroids and antibiotics in primary care: A systematic review of current copd guidelines

npj Primary Care Respiratory Medicine

Volumn 25, Issue , 2015, Pages 1-8

  Laue, Johanna ^a   Reierth, Eirik ^a   Melbye, Hasse ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BRONCHODILATING AGENT; C REACTIVE PROTEIN; CORTICOSTEROID; PROCALCITONIN; ANTIINFECTIVE AGENT;

ARTICLE; BLOOD GAS ANALYSIS; BREATHING RATE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COUGHING; DISEASE EXACERBATION; DYSPNEA; HEALTH CARE PERSONNEL; HEART RATE; HOSPITALIZATION; HUMAN; LEUKOCYTE COUNT; META ANALYSIS (TOPIC); PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PULSE OXIMETRY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPUTUM; SYSTEMATIC REVIEW; THORAX RADIOGRAPHY; WHEEZING; DISEASE COURSE; PRIMARY HEALTH CARE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ADRENAL CORTEX HORMONES; ANTI-BACTERIAL AGENTS; DISEASE PROGRESSION; HUMANS; PRACTICE GUIDELINES AS TOPIC; PRIMARY HEALTH CARE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84991963163     PISSN: None     EISSN: 20551010     Source Type: Journal    
DOI: 10.1038/npjpcrm.2015.2     Document Type: Article

References (79)

1. O'Reilly JF, Williams AE, Holt K, Rice L. Defining COPD exacerbations: impact on estimation of incidence and burden in primary care. Prim Care Respir J 2006; 15: 346–353
2. Jeppesen E, Brurberg KG, Vist GE, Wedzicha JA, Wright JJ, Greenstone M et al. Hospital at home for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 5: CD003573
3. Walters JA, Gibson PG, Wood-Baker R, Hannay M, Walters EH. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2009; 1: CD001288
4. Vollenweider DJ, Jarrett H, Steurer-Stey CA, Garcia-Aymerich J, Puhan MA. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 12: CD010257
5. Puhan M, Vollenweider D, Steurer J, Bossuyt P, ter Riet G. Where is the supporting evidence for treating mild to moderate chronic obstructive pulmonary disease exacerbations with antibiotics? A systematic review. BMC Med 2008; 6: 28
6. Goossens H, Ferech M, Vander Stichele R, Elseviers M. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet 2005; 365: 579–587
7. Bach PB, Brown C, Gelfand SE, McCrory DC. Management of acute exacerbations of chronic obstructive pulmonary disease: a summary and appraisal of published evidence. Ann Intern Med 2001; 134: 600–620
8. Graham R, Mancher M, Wolman MD, Greenfield S, Steinberg E (eds). Clinical Practice Guidelines We Can Trust. The National Academies Press: Washington DC, USA, 2011
9. Lacasse Y, Ferreira I, Brooks D, Newman T, Goldstein RS. Critical appraisal of clinical practice guidelines targeting chronic obstructive pulmonary disease. Arch Intern Med 2001; 161: 69–74
10. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097
11. Brouwers MC, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G et al. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ 2010; 182: E839–E842
12. Albert RK, Martin TR, Lewis SW. Controlled clinical trial of methylprednisolone in patients with chronic bronchitis and acute respiratory insufficiency. Ann Intern Med 1980; 92: 753–758
13. Thompson WH, Nielson CP, Carvalho P, Charan NB, Crowley JJ. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med 1996; 154: 407–412
14. Niewoehner DE, Erbland ML, Deupree RH, Collins D, Gross NJ, Light RW et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1999; 340: 1941–1947
15. Davies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 1999; 354: 456–460
16. Maltais F, Ostinelli J, Bourbeau J, Tonnel AB, Jacquemet B, Haddon J et al. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med 2002; 165: 698–703
17. Aaron SD, Vandemheen KL, Hebert P, Dales R, Stiell IG, Ahuja J et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med 2003; 348: 2618–2625
18. de Jong YP, Uil SM, Grotjohan HP, Postma DS, Kerstjens HA, van den Berg JW. Oral or IV prednisolone in the treatment of COPD exacerbations: a randomized, controlled, double-blind study. Chest 2007; 132: 1741–1747
19. Gunen H, Hacievliyagil SS, Yetkin O, Gulbas G. The role of nebulised budesonide in the treatment of acute exacerbations of COPD. Eur Respir J 2007; 30: 399–400
20. Ställberg B, Selroos O, Vogelmeier C, Andersson E, Ekstrom T, Larsson K. Budesonide/ formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD. A double-blind, randomised, non-inferiority, parallel-group, multicentre study. Respir Res 2009; 10: 11
21. Alia I, de la Cal MA, Esteban A, Abella A, Ferrer R, Molina FJ et al. Efficacy of corticosteroid therapy in patients with an acute exacerbation of chronic obstructive pulmonary disease receiving ventilatory support. Arch Intern Med 2011; 171: 1939–1946
22. Leuppi JD, Schuetz P, Bingisser R, Bodmer M, Briel M, Drescher T et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the reduce randomized clinical trial. JAMA 2013; 309: 2223–2231
23. Gupta D, Agarwal R, Aggarval A, Maturu VN, Dhooria S, Prasad KT et al. Guidelines for diagnosis and management of chronic obstructive pulmonary disease: Joint ICS/NCCP (I) recommendations. Lung India 2013; 30: 228–267
24. Khan JH, Lababidi HM, Al-Moamary MS, Zeitouni MO, Al-Jadhali HH, Al-Amoudi OS et al. The Saudi Guidelines for the Diagnosis and Management of COPD. Ann Thorac Med 2014; 9: 55–76
25. Anthonisen N, Manfreda J, Warren C. Antiobiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196–204
26. Seemungal T, Harper-Owen R, Bhowmik A, Moric I, Sanderson G, Message S et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164: 1618–1623
27. Patel IS, Seemungal TA, Wilks M, Lloyd-Owen SJ, Donaldson GC, Wedzicha JA. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 2002; 57: 759–764
28. Nouira S, Marghli S, Belghith M, Besbes L, Elatrous S, Abroug F. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial. Lancet 2001; 358: 2020–2025
29. Berry DG, Fry J, Hindley CP, Hodson JM, Horder EJ, Horder JP et al. Exacerbations of chronic bronchitis treatment with oxytetracycline. Lancet 1960; 1: 137–139
30. Fear E, Edwards G. Antibiotic regimens in chronic bronchitis. Br J Dis Chest 1962; 56: 153–162
31. Elmes P, King T, Langlands J. Value of ampicillin in the hospital treatment of exacerbations of chronic bronchitis. Br Med J 1965; 2: 904–908
32. Pines A, Raafat H, Plucinski K, Greenfield J, Solari M. Antibiotic regimens in severe and acute purulent exacerbations of chronic bronchitis. BMJ 1968; 2: 735–738
33. Pines A, Raafat H, Greenfield JS, Linsell WD, Solari ME. Antibiotic regimens in moderately ill patients with purulent exacerbations of chronic bronchitis. Br J Dis Chest 1972; 66: 107–115
34. Manresa F, Blavia R, Martin R, Linares J, Rodriguez B, Verdaguer R. Antibiotics for exacerbations of chronic bronchitis. Lancet 1987; 2: 394–395
35. Jørgensen AF, Coolidge J, Pedersen PA, Petersen KP, Waldorff S, Widding E. Amoxicillin in treatment of acute uncomplicated exacerbations of chronic bronchitis. A double-blind, placebo-controlled multicentre study in general practice. Scand J Prim Health Care 1992; 10: 7–11
36. Sachs AP, Koëter GH, Groenier KH, van der Waaij D, Schiphuis J, Meyboom-de Jong B. Changes in symptoms, peak expiratory flow, and sputum flora during treatment with antibiotics of exacerbations in patients with chronic obstructive pulmonary disease in general practice. Thorax 1995; 50: 758–763
37. Brusse-Keizer M, van der Valk P, Hendrix R, Kerstjens H, van der Pale J. Antibiotics in patients with a mild to moderate home-treated COPD exacerbation: the ABC trial. Am J Respir Crit Care Med 2009; 179: Abstract 1493
38. Daniels JM, Snijders D, de Graaff CS, Vlaspolder F, Jansen HM, Boersma WG. Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 181: 150–157
39. Llor C, Bjerrum L, Munck A, Hansen MP, Cordoba GC, Strandberg EL et al. Predictors for antibiotic prescribing in patients with exacerbations of COPD in general practice. Ther Adv Respir Dis 2013; 7: 131–137
40. Schott G, Dünnweber C, Mühlbauer B, Niebling W, Pachl H, Ludwig W. Does the pharmaceutical industry influence guidelines? Two examples from Germany. Dtsch Arztebl Int 2013; 110: 575–583
41. Iqbal A, Schloss S, George D, Isonaka S. Worldwide guidelines for chronic obstructive pulmonary disease: a comparison of diagnosis and treatment recommendations. Respirology 2002; 7: 233–239
42. Miravitlles M, Anzueto A, Ewig S, Legnani D, Stauch K. Characterisation of exacerbations of chronic bronchitis and COPD in Europe: the GIANT study. Ther Adv Respir Dis 2009; 3: 267–277
43. Herland K, Akselsen J-P, Skjønsberg OH, Bjermer L. How representative are clinical study patients with asthma or COPD for a larger “real life” population of patients with obstructive lung disease? Respir Med 2005; 99: 11–19
44. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000; 117: 398–401
45. Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J, Howard P et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD): a consensus statement of the European Respiratory Society. Eur Respir J 1995; 8: 1398–1420
46. Bullard MJ, Liaw SJ, Tsai YH, Min HP. Early corticosteroid use in acute exacerbations of chronic airflow obstruction. Am J Emerg Med 1996; 14: 139–143
47. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187: 347–365
48. Allegra L, Blasi F, Diano P, Consentini R, Tarsia P, Confalonieri M et al. Sputum color as a marker of acute bacterial exacerbations of chronic obstructive pulmonary disease. Respir Med 2005; 99: 742–747
49. Miravitlles M, Moragas A, Hernandez S, Bayona C, Llor C. Is it possible to identify exacerbations of mild to moderate COPD that do not require antibiotic treatment? Chest 2013; 144: 1571–1577
50. Brusse-Keizer MG, Grotenhuis AJ, Kerstjens HA, Telgen MC, van der Palen J, Hendrix MG et al. Relation of sputum colour to bacterial load in acute exacerbations of COPD. Respir Med 2009; 103: 601–606
51. Koutsokera A, Stolz D, Loukides S, Kostikas K. Systemic biomarkers in exacerbations of copd: the evolving clinical challenge. Chest 2012; 141: 396–405
52. Nyström P. The systemic inflammatory response syndrome: definitions and aetiology. J Antimicrob Chemother 1998; 41: 1–7
53. McNally M, Curtain J, O'Brien KK, Dimitrov BD, Fahey T. Validity of British Thoracic Society guidance (the CRB-65 rule) for predicting the severity of pneumonia in general practice: systematic review and meta-analysis. Br J Gen Pract 2010; 60: e423–e433
54. Edwards L, Perrin K, Wijesinghe M, Weatherall M, Beasley R, Travers J. The value of the CRB65 score to predict mortality in exacerbations of COPD requiring hospital admission. Respirology 2011; 16: 625–629
55. Lacoma A, Prat C, Andreo F, Lores L, Ruiz-Manzano J, Ausina V et al. Value of procalcitonin, C-reactive protein, and neopterin in exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2011; 6: 157–169
56. Schuetz P, Christ-Crain M, Thomann R, Falconnier C, Wolbers M, Widmer I et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009; 302: 1059–1066
57. Bafadhel M, Clark TW, Reid C, Medina MJ, Batham S, Barer MR et al. Procalcitonin and C-reactive protein in hospitalized adult patients with community-acquired pneumonia or exacerbation of asthma or COPD. Chest 2011; 139: 1410–1418
58. Daniels JMA, Schoorl M, Snijders D, Knol DL, Lutter R, Jansen HM et al. Procalcitonin vs c-reactive protein as predictive markers of response to antibiotic therapy in acute exacerbations of COPD. Chest 2010; 138: 1108–1115
59. Stolz D, Christ-Crain M, Bingisser R, Leuppi J, Miedinger D, Muller C et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007; 131: 9–19
60. Miravitlles M, Calle M, Soler-Cataluña JJ. Clinical Phenotypes of COPD: Identification, Definition and Implications for Guidelines. Arch Bronconeumol 2012; 48: 86–98
61. Block LH, Burghuber OC, Hartl S, Zwick H. Österreichische Gesellschaft für Lungenerkrankungen und Tuberkulose: Konsensus zum Management der chronisch obstruktiven Lungenerkrankung (COPD). Wien Klin Wochenschr 2004; 116: 268–278
62. Bellamy D, Bouchard J, Henrichsen S, Johansson G, Langhammer A, Reid J et al. International Primary Care Respiratory Group (IPCRG) Guidelines: management of chronic obstructive pulmonary disease (COPD). Prim Care Respir J 2006; 15: 48–57
63. Sundhedsstyrelsen. KOL-Kronisk Obstruktiv Lungesygdom. Anbefalinger for Tidlig Opsporing, Opfølgning, Behandling og Rehabilitering. Sundhedsstyrelsen: København, Denmark, 2007
64. Smeele I, Van Weel C, Van Schayck C, Van der Molen T, Thoonen B, Schermer T et al. De standaard en de wetenschappelijke verantwoording zijn geactualiseerd ten opzichte van de vorige versies van de NHG-Standaarden COPD en astma bij volwassenen: diagnostiek (Huisarts Wet 2001;44;107-17) en COPD: behandling (Huisarts Wet 2001;44;207-19). Huisarts Wet 2007; 50: 362–379.
65. Läkemedelsverket. Farmakologisk behandling av kroniskt obstruktiv lungesjukdom- KOL. Information från Läkemedelsverket 2009; 2: 13–28
66. Höffken G, Lorenz J, Kern W, Welte T, Bauer T, Dalhoff K et al. [Epidemiology, diagnosis, antimicrobial therapy and management of community-acquired pneumonia and lower respiratory tract infections in adults. Guidelines of the Paul- Ehrlich-Society for Chemotherapy, the German Respiratory Society, the German Society for Infectiology and the Competence Network CAPNETZ Germany]. Pneumologie 2009; 63: e1–68
67. National Clinical Guideline Centre. (2010) Chronic Obstructive Pulmonary Disease: Management of Chronic Obstructive Pulmonary Disease in Adults in Primary and Secondary Care. London: National Clinical Guideline Centre. http://guidance.nice. org.uk/CG101/Guidance/pdf/English.
68. Abdool-Gaffar MS, Ambaram A, Ainslie GM, Bolliger CT, Feldman C, Geffen L et al. Guideline for the management of chronic obstructive pulmonary disease- 2011 update. S Afr Med J 2011; 101: 63–73
69. Guidelines and Protocols Advisory Committee. Chronic Obstructive Pulmonary Disease (COPD). British Columbia Medical Association, Medical Services Commission: Victoria, BC, Canada, 2011
70. Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M et al. Guidelines for the management of adult lower respiratory tract infections-Full version. Clin Microbiol Infect 2011; 17: 1–59
71. McKenzie DK, Abrahamson M, Crockett AJ, Dabscheck E, Glasgow N, Jenkins S et al. The Australian Lung Foundation. The COPD X-Plan: Australian and New QZealand Guidelines for the management of Chronic Obstructive Pulmonary Disease V2.32,2011
72. Helsedirektoratet. KOLS-Nasjonal Faglig Retningslinje og Veileder for Forebygging, Diagnostisering og Oppfølging av Personer med kols. Helsedirektoratet: Oslo, Norway, 2012
73. Russi EW, Karrer W, Brutsche M, Eich C, Fitting JW, Frey M et al. Diagnosis and management of chronic obstructive pulmonary disease: the Swiss guidelines. Official guidelines of the Swiss Respiratory Society. Respiration 2013; 85: 160–174
74. Anderson B, Conner K, Dunn C, Kerestes G, Lim K, Myers C. et al. Diagnosis and Management of Chronic Obstructive Pulmonary Disease (COPD). Bloomington, MN, USA: Institute for Clinical Systems Improvement, 2013
75. Global Initiative for Chronic Obstructive Lung Disease Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Vancouver, WA, USA: GOLD, 2013
76. Stoller JK. Management of acute exacerbations of chronic obstructive pulmonary disease. UpToDate 2013
77. Bartlett JG, Sethi S. Management of infection in acute exacerbations of chronic obstructive pulmonary disease. UpToDate 2013
78. Miravitlles M, Soler-Cataluna JJ, Calle M, Molina J, Almagro P, Quintano JA et al. Spanish guideline for COPD (GesEPOC). Update 2014. Arch Bronconeumol 2014; 50(Suppl 1): 1–16
79. Emerman CL, Connors AF, Lukens TW, May ME, Effron D. A randomized controlled trial of methylprednisolone in the emergency treatment of acute exacerbations of COPD. Chest 1989; 95: 563–567.